Future approaches in CRPC: radioligands, CAR-T and bispecifics

What are the differences between CAR T-cell therapy and bispecific antibodies?Подробнее

Novel approaches in Richter's transformation: CAR-T and bispecificsПодробнее

The CAR T-cell strategy vs bispecific antibodiesПодробнее

Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodiesПодробнее

Combining CAR-Ts & bispecific antibodiesПодробнее

CAR T-cell Therapy explained (Manufacturing process & how it works)Подробнее

Bispecifics & CAR-T therapy in DLBCL: sequencing and selecting between these agentsПодробнее

CAR T-Cell Therapy: How Does It Work?Подробнее

The future of CAR T-cells and bispecific antibodies to treat myelomaПодробнее

CAR T-cell Cytotoxicity of Solid Tumors is Dependent on IFNγR Signaling & Downstream AdhesionПодробнее

How to best sequence bispecific antibodies and CAR-T therapy in multiple myelomaПодробнее

CAR T Cells: Beating Cancer with the Immune SystemПодробнее

Q&A | How to sequence CAR T-cell therapy and bispecific antibodies in R/R MMПодробнее

The possibility of combining CAR-T therapy and bispecific antibodies in the treatment of NHLПодробнее

Cancer Cells: CAR T Cells Targeting by Real Time Potency Assay | Protocol PreviewПодробнее

Developing the next generation of CAR-T cellsПодробнее

Cell Therapy: Decoding CAR-TПодробнее

Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myelomaПодробнее

What is CAR T-Cell Therapy? What Cancer Patients NEED to Know!Подробнее